HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination

Cancer Immunology, Immunotherapy

Volumn 56, Issue 5, 2007, Pages 709-717

  Cabrera, Teresa ^a,b   Lara, Ester ^a,b   Romero, José M ^a,b   Maleno, Isabel ^a   Real, Luis M ^c   Ruiz Cabello, Francisco ^a,b   Valero, Pedro ^d   Camacho, Francisco M ^e   Garrido, Federico ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

^d Infanta Luisa Hospital   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Cancer; HLA; Immunotherapy; Melanoma; Metastasis

Indexed keywords

ALPHA2B INTERFERON; DACARBAZINE; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIBODY; HLA ANTIGEN; HLA ANTIGEN CLASS 1; MELANOMA VACCINE; MESSENGER RNA; MONOCLONAL ANTIBODY; RECOMBINANT ALPHA2B INTERFERON; TEMOZOLOMIDE;

ANTIGEN EXPRESSION; ARTICLE; BETA CHAIN; CANCER IMMUNIZATION; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CARCINOGENESIS; CASE REPORT; DISEASE COURSE; DRUG MEGADOSE; HEAVY CHAIN; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN METASTASIS; STAINING; TUMOR GROWTH;

CANCER VACCINES; DISEASE PROGRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MELANOMA; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR ESCAPE;

EID: 33847387112     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0226-7     Document Type: Article

References (31)

1. Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267-268
2. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380-384
3. Coulie PG, van der Bruggen P (2003) T cell responses of vaccinated cancer patients. Curr Opin Immunol 15:131-137
4. Berd D (2004) M-VAX: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 3:521-527
5. Marchand M, Brichard V, van Baren N, Coulie PG (2001) Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther 1:497-510
6. Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, Fais S, Lozupone F, Casati C, Castelli C, Parmiani G (2005) Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 5:463-476
7. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T (2004) Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101(Supp12):14631-14638
8. Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor 1ymphocytes. Proc Natl Acad Sci USA 101(Supp12):14639-14645
9. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101(Supp12):14567-14571
10. Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H (2005) Phase I/II study of immunotherapy with T cell peptide epitopes in patients with stage IV me1anoma. Cancer Immunol Immunother 54:208-218
11. Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F (1988) Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 5:203-212
12. Kageshita T, Ishihara T, Campoli M, Ferrone S (2005) Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65:419-428
13. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, López-Botet M, Duggan-Keen M. Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89-95
14. Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F (1998) Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520-529
15. Mendez R, Serrano A, Jager E, Maleno I, Ruiz-Cabello F, Knuth A, Garrido F (2001) Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens 57:508-519
16. Mendez R, Ruiz-Cabello F, Rodriguez T, Del Campo A, Paschen A, Schadendorf D, Garrido F (2006) Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother [Epub ahead of print]
17. Maleno I, Cabrera CM, Cabrera T, López-Nevot MA, Collado A, Ferrón A, Garrido F (2004) Distribution of HLA class I phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 56:244-253
18. Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807-839
19. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999-1005
20. Tait BD (2000) HLA class I expression on human cancer cells. Hum Immunol 61:158-165
21. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 10:904-910
22. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′- deoxycytidine treatment. Int J Cancer 94:243-251
23. Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103:759-767
24. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66:6405-6411
25. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340-347
26. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100-108
27. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109-119
28. Griffioen M, Ouwerkerk IJ, Harten V, Schrier PI (2000) HLA-B locus-specific downregulation in human melanoma requires enhancer A as well as a sequence element located downstream of the transcription initiation site. Immunogenetics 52:121-128
29. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117:248-255
30. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118:6-10
31. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G (2002) Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 188:97-113